



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

12<sup>th</sup> November, 2019

Corporate Relationship Department  
M/s. BSE Ltd  
Dalal Street, Fort  
**Mumbai- 400 001**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) **Mumbai -400 051**

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed the Press Release for your information.

Thanking you

Yours faithfully  
For NATCO Pharma Limited

A handwritten signature in blue ink, appearing to read "M Adinarayana".

M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp Affairs)



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/13/2019-2020

PRESS RELEASE

**NATCO records INR 518.9 Crore consolidated revenue and INR 117.7 Crore of profit, after tax, for the Second Quarter, FY2019-20**

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 518.9 Crore for the Second quarter ended on 30<sup>th</sup> September, 2019, as against INR 583.50 Crore for the same period last year. The net profit for the period, on a consolidated basis, was INR 117.7 Crores as against INR 181.6 Crore same period last year. The decline in revenues and profits compared to the same period last year is primarily due to the anticipated drop in oseltamivir product sales in the USA and Hep C sales in India.

Segmental Revenue Split (approx.), for the Quarter 2, FY2019-20, as below-

Segment	Revenue (INR crore), Q2 FY20
API	68
Formulations, Domestic	122
Formulations, Exports (incl. Profit Share)	225
Foreign Subsidiaries	27
Other Operating income	43
Other Income	34

The Board of Directors has recommended second interim dividend of INR 1.00 per equity share of INR 2.00 each.

---

Forwarded for favour of publication  
For NATCO PHARMA LIMITED

M. Adinarayana  
Company Secretary &  
Vice President (Legal & Corp. Affairs)